Characterization of rabies virus strains used for vaccine production by means of monoclonal antibodies.
A group of WHO Consultants who met in Geneva 16-18 September 1982, recommended, among other items, that "monoclonal antibody reactivity pattern of all viruses used for (rabies) vaccine production should be established" (WHO/Rab.Res./82.15) (1). Such a study has been undertaken in our WHO Collaborative Centre for Rabies in close collaboration with the WHO Collaborative Centre for Rabies of the Wistar Institute, and with monoclonal antibodies kindly supplied by T.J. Wiktor (2).
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D000956:Antigens, Viral / Q000276:immunology; D002213:Capsid / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D006023:Glycoproteins / Q000276:immunology; D011819:Rabies Vaccines / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology*; D013045:Species Specificity; D014764:Viral Proteins / Q000276:immunology
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000956:Antigens, Viral; D000939:Epitopes; D006023:Glycoproteins; D011819:Rabies Vaccines; D014764:Viral Proteins